Literature DB >> 19954384

High-density lipoprotein particles and markers of inflammation and thrombotic activity in patients with untreated HIV infection.

Jason Baker1, Woubeshet Ayenew, Harrison Quick, Katherine Huppler Hullsiek, Russell Tracy, Keith Henry, Daniel Duprez, James D Neaton.   

Abstract

BACKGROUND: Untreated human immunodeficiency virus (HIV) infection is associated with changes in blood lipids, inflammation, thrombotic activity, and increased risk for cardiovascular disease.
METHODS: We studied high-density lipoprotein particle (HDLp) concentrations and inflammatory (high-sensitivity C-reactive protein [hsCRP] and interleukin [IL] 6), endothelial activation (E-selectin and soluble intercellular adhesion molecule-1 [sICAM-1]), and thrombotic (fibrinogen and D-dimer) biomarkers in a group of 32 untreated HIV-infected and 29 uninfected persons. Differences in the levels of blood lipids and biomarkers by HIV status were examined before and after adjustment for age, sex, race/ethnicity, smoking status, body mass index, and the presence of hepatitis C.
RESULTS: HIV-infected participants, compared with uninfected participants, had lower HDL cholesterol (HDLc) levels (-26%) and HDLp numbers (-21%), with reductions in large (-50%) and small (-20%) HDLp, specifically (P < or = .01 for all). A trend was present for higher total cholesterol (P = .15 and triglyceride levels (P = .11) among individuals with HIV infection. Levels of IL-6, sICAM-1, and D-dimer were 65%-70% higher in HIV-infected participants (P < or = .02 for all). Covariate adjustment did not diminish these associations. For HIV-infected participants, total and small HDLp (respectively) tended to correlate inversely with levels of IL-6 (P = .08 and P = .02), sICAM-1 (P < .01 for both) and D-dimer (P = .03 and p < .01).
CONCLUSIONS: Persons with untreated HIV infection have lower HDLp (primarily large and small HDLp) and higher IL-6, sICAM-1, and D-dimer levels, and the relationship of these markers to HIV-mediated atherosclerotic risk requires further study.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19954384      PMCID: PMC2798007          DOI: 10.1086/649560

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  48 in total

Review 1.  Epidemiological evidence for inflammation in cardiovascular disease.

Authors:  R P Tracy
Journal:  Thromb Haemost       Date:  1999-08       Impact factor: 5.249

2.  Fibrin D-dimer and coronary heart disease: prospective study and meta-analysis.

Authors:  J Danesh; P Whincup; M Walker; L Lennon; A Thomson; P Appleby; A Rumley; G D Lowe
Journal:  Circulation       Date:  2001-05-15       Impact factor: 29.690

Review 3.  Infection and inflammation-induced proatherogenic changes of lipoproteins.

Authors:  W Khovidhunkit; R A Memon; K R Feingold; C Grunfeld
Journal:  J Infect Dis       Date:  2000-06       Impact factor: 5.226

4.  Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events.

Authors:  Paul M Ridker; Nader Rifai; Lynda Rose; Julie E Buring; Nancy R Cook
Journal:  N Engl J Med       Date:  2002-11-14       Impact factor: 91.245

5.  Circulating cell adhesion molecules and death in patients with coronary artery disease.

Authors:  S Blankenberg; H J Rupprecht; C Bickel; D Peetz; G Hafner; L Tiret; J Meyer
Journal:  Circulation       Date:  2001-09-18       Impact factor: 29.690

6.  Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men.

Authors:  P M Ridker; N Rifai; M J Stampfer; C H Hennekens
Journal:  Circulation       Date:  2000-04-18       Impact factor: 29.690

7.  Lipoprotein particle subclasses, cardiovascular disease and HIV infection.

Authors:  Daniel A Duprez; Lewis H Kuller; Russell Tracy; James Otvos; David A Cooper; Jennifer Hoy; Jacqueline Neuhaus; Nicholas I Paton; Nina Friis-Moller; Fiona Lampe; Angelike P Liappis; James D Neaton
Journal:  Atherosclerosis       Date:  2009-05-13       Impact factor: 5.162

8.  Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial.

Authors:  Robert S Rosenson; James D Otvos; David S Freedman
Journal:  Am J Cardiol       Date:  2002-07-15       Impact factor: 2.778

9.  Nuclear magnetic resonance spectroscopy of lipoproteins and risk of coronary heart disease in the cardiovascular health study.

Authors:  Lewis Kuller; Alice Arnold; Russell Tracy; James Otvos; Greg Burke; Bruce Psaty; David Siscovick; David S Freedman; Richard Kronmal
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-07-01       Impact factor: 8.311

10.  Coagulation and activation of inflammatory pathways in the development of functional decline and mortality in the elderly.

Authors:  Harvey Jay Cohen; Tamara Harris; Carl F Pieper
Journal:  Am J Med       Date:  2003-02-15       Impact factor: 4.965

View more
  51 in total

1.  Interleukin-6 and d-dimer levels are associated with vascular dysfunction in patients with untreated HIV infection.

Authors:  J Baker; H Quick; K H Hullsiek; R Tracy; D Duprez; K Henry; J D Neaton
Journal:  HIV Med       Date:  2010-06-28       Impact factor: 3.180

Review 2.  Management of the metabolic effects of HIV and HIV drugs.

Authors:  Todd T Brown; Marshall J Glesby
Journal:  Nat Rev Endocrinol       Date:  2011-09-20       Impact factor: 43.330

3.  HIV status, burden of comorbid disease, and biomarkers of inflammation, altered coagulation, and monocyte activation.

Authors:  Kaku A Armah; Kathleen McGinnis; Jason Baker; Cynthia Gibert; Adeel A Butt; Kendall J Bryant; Matthew Goetz; Russell Tracy; Krisann K Oursler; David Rimland; Kristina Crothers; Maria Rodriguez-Barradas; Steve Crystal; Adam Gordon; Kevin Kraemer; Sheldon Brown; Mariana Gerschenson; David A Leaf; Steven G Deeks; Charles Rinaldo; Lewis H Kuller; Amy Justice; Matthew Freiberg
Journal:  Clin Infect Dis       Date:  2012-04-24       Impact factor: 9.079

4.  HIV, HAART, and lipoprotein particle concentrations in the Women's Interagency HIV Study.

Authors:  Phyllis C Tien; Michael F Schneider; Christopher Cox; Mardge Cohen; Roksana Karim; Jason Lazar; Mary Young; Marshall J Glesby
Journal:  AIDS       Date:  2010-11-27       Impact factor: 4.177

Review 5.  Biomarkers and HIV-associated cardiovascular disease.

Authors:  Jason V Baker; Daniel Duprez
Journal:  Curr Opin HIV AIDS       Date:  2010-11       Impact factor: 4.283

Review 6.  Biomarkers of immune dysfunction in HIV.

Authors:  Daniel E Nixon; Alan L Landay
Journal:  Curr Opin HIV AIDS       Date:  2010-11       Impact factor: 4.283

Review 7.  Cardiovascular implications from untreated human immunodeficiency virus infection.

Authors:  Jason V Baker; Jens D Lundgren
Journal:  Eur Heart J       Date:  2011-01-12       Impact factor: 29.983

Review 8.  Risk of coronary heart disease in patients with HIV infection.

Authors:  Markella V Zanni; Judith Schouten; Steven K Grinspoon; Peter Reiss
Journal:  Nat Rev Cardiol       Date:  2014-10-21       Impact factor: 32.419

9.  Immunosuppression and HIV Viremia Associated with More Atherogenic Lipid Profile in Older People with HIV.

Authors:  Matthew E Levy; Alan E Greenberg; Manya Magnus; Naji Younes; Amanda Castel
Journal:  AIDS Res Hum Retroviruses       Date:  2018-11-27       Impact factor: 2.205

10.  Aggregate risk of cardiovascular disease among adolescents perinatally infected with the human immunodeficiency virus.

Authors:  Kunjal Patel; Jiajia Wang; Denise L Jacobson; Steven E Lipshultz; David C Landy; Mitchell E Geffner; Linda A Dimeglio; George R Seage; Paige L Williams; Russell B Van Dyke; George K Siberry; William T Shearer; Luciana Young; Gwendolyn B Scott; James D Wilkinson; Stacy D Fisher; Thomas J Starc; Tracie L Miller
Journal:  Circulation       Date:  2013-12-23       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.